Ephedra in Texas
This article was originally published in The Tan Sheet
Thirty-three warning letters have been sent by Texas Department of Public Health to companies failing to comply with rule requiring ephedrine alkaloid-containing supplements bear a warning against sales to individuals under age 18 and include FDA's MedWatch number on labeling for AE reporting. Nine companies have come into compliance, approximately 10 referred to the Texas AG's office, with the rest pending, department says. Officials say they have not noticed an increase in AE reports since the rule became effective Sept. 1 (1"The Tan Sheet" Sept. 10, 2001, In Brief)...
You may also be interested in...
Texas Dept. of Health's enforcement of ephedrine rule, which requires supplement labeling to carry FDA's MedWatch number and warning against sales to persons 17 or younger, commenced Sept. 1, DoH confirms Sept. 6. "Whether or not enforcement will include detaining mislabeled products will be determined on a case-by-case basis," department says. Similar provisions have been added to California bill making its way through state legislature. SB 397 cleared Senate June 7. Amendments added during Assembly Health Committee review restrict ephedrine sales to people over 18 and require MedWatch number on label. Assembly Appropriations Cmte. slated to review bill week of Sept. 10
The US agency has announced another month of webinars aimed at labs and manufacturers that are developing – or have developed – diagnostic tests for the novel coronavirus.
The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.